{"id":"https://openalex.org/W1968255247","doi":"https://doi.org/10.1097/00042560-200201010-00002","title":"Dioxolane Guanosine, the Active Form of the Prodrug Diaminopurine Dioxolane, Is a Potent Inhibitor of Drug-Resistant HIV-1 Isolates From Patients for Whom Standard Nucleoside Therapy Fails","display_name":"Dioxolane Guanosine, the Active Form of the Prodrug Diaminopurine Dioxolane, Is a Potent Inhibitor of Drug-Resistant HIV-1 Isolates From Patients for Whom Standard Nucleoside Therapy Fails","publication_year":2002,"publication_date":"2002-01-01","ids":{"openalex":"https://openalex.org/W1968255247","doi":"https://doi.org/10.1097/00042560-200201010-00002","mag":"1968255247","pmid":"https://pubmed.ncbi.nlm.nih.gov/11782585"},"language":"en","primary_location":{"id":"doi:10.1097/00042560-200201010-00002","doi":"https://doi.org/10.1097/00042560-200201010-00002","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00042560-200201010-00002","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059903322","display_name":"Jennifer P. Mewshaw","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267007","display_name":"Triangle Pharmaceuticals, Inc. (United States)","ror":"https://ror.org/00sd5cy44","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267007"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jennifer P. Mewshaw","raw_affiliation_strings":["Triangle Pharmaceuticals, Durham, North Carolina, USA","Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Triangle Pharmaceuticals, Durham, North Carolina, USA","institution_ids":["https://openalex.org/I4405267007"]},{"raw_affiliation_string":"Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A","institution_ids":["https://openalex.org/I4405267007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001289644","display_name":"Florence T. Myrick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267007","display_name":"Triangle Pharmaceuticals, Inc. (United States)","ror":"https://ror.org/00sd5cy44","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267007"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Florence T. Myrick","raw_affiliation_strings":["Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A","institution_ids":["https://openalex.org/I4405267007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040190415","display_name":"Debby A. C. S. Wakefield","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267007","display_name":"Triangle Pharmaceuticals, Inc. (United States)","ror":"https://ror.org/00sd5cy44","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267007"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Debby A. C. S. Wakefield","raw_affiliation_strings":["Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A","institution_ids":["https://openalex.org/I4405267007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003179235","display_name":"Brandi J. Hooper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267007","display_name":"Triangle Pharmaceuticals, Inc. (United States)","ror":"https://ror.org/00sd5cy44","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267007"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Brandi J. Hooper","raw_affiliation_strings":["Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A","institution_ids":["https://openalex.org/I4405267007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001293746","display_name":"Jeanette L. Harris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267007","display_name":"Triangle Pharmaceuticals, Inc. (United States)","ror":"https://ror.org/00sd5cy44","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267007"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jeanette L. Harris","raw_affiliation_strings":["Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A","institution_ids":["https://openalex.org/I4405267007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043678851","display_name":"Bruce J. McCreedy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce McCreedy","raw_affiliation_strings":["Therapy Edge, Research Triangle Park, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Therapy Edge, Research Triangle Park, North Carolina, U.S.A","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010901896","display_name":"Katyna Borroto\u2013Esoda","orcid":"https://orcid.org/0000-0002-3909-6578","observed_orcids":["https://orcid.org/0000-0002-3909-6578"]},"institutions":[{"id":"https://openalex.org/I4405267007","display_name":"Triangle Pharmaceuticals, Inc. (United States)","ror":"https://ror.org/00sd5cy44","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267007"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Katyna Borroto-Esoda","raw_affiliation_strings":["Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A","and reprint requests to Katyna Borroto-Esoda, Triangle Pharmaceuticals, 4 University Place, 4611 University Drive, Durham, NC 27707, U.S.A.; e-mail: [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Triangle Pharmaceuticals, Durham, and \u2020Therapy Edge, Research Triangle Park, North Carolina, U.S.A","institution_ids":["https://openalex.org/I4405267007"]},{"raw_affiliation_string":"and reprint requests to Katyna Borroto-Esoda, Triangle Pharmaceuticals, 4 University Place, 4611 University Drive, Durham, NC 27707, U.S.A.; e-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4405267007"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5001289644","https://openalex.org/A5001293746","https://openalex.org/A5003179235","https://openalex.org/A5010901896","https://openalex.org/A5040190415","https://openalex.org/A5059903322"],"corresponding_institution_ids":["https://openalex.org/I4405267007"],"apc_list":null,"apc_paid":null,"fwci":6.845,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.97247706,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"29","issue":"1","first_page":"11","last_page":"20"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.8820000290870667},{"id":"https://openalex.org/keywords/drug-resistant-hiv-1","display_name":"drug-resistant HIV-1","score":0.6959999799728394},{"id":"https://openalex.org/keywords/nucleoside-reverse-transcriptase-inhibitors","display_name":"nucleoside reverse transcriptase inhibitors","score":0.9240000247955322},{"id":"https://openalex.org/keywords/antiviral-activity","display_name":"antiviral activity","score":0.7129999995231628},{"id":"https://openalex.org/keywords/adenosine-deaminase","display_name":"adenosine deaminase","score":0.9179999828338623},{"id":"https://openalex.org/keywords/resistance-mutations","display_name":"resistance mutations","score":0.6549999713897705},{"id":"https://openalex.org/keywords/k65r","display_name":"K65R","score":0.7519999742507935},{"id":"https://openalex.org/keywords/multidrug-resistance","display_name":"multidrug resistance","score":0.7940000295639038},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.6790000200271606},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.5299999713897705}],"concepts":[{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.894894540309906},{"id":"https://openalex.org/C2776666804","wikidata":"https://www.wikidata.org/wiki/Q2234483","display_name":"Dioxolane","level":2,"score":0.7008987665176392},{"id":"https://openalex.org/C2777995097","wikidata":"https://www.wikidata.org/wiki/Q422462","display_name":"Guanosine","level":2,"score":0.6547852158546448},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5197843909263611},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.511963963508606},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.5118252635002136},{"id":"https://openalex.org/C2777333352","wikidata":"https://www.wikidata.org/wiki/Q2689559","display_name":"Nucleoside analogue","level":3,"score":0.48917916417121887},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4828091859817505},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.47225016355514526},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.3946847915649414},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2893860340118408},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.21876013278961182},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07462918758392334},{"id":"https://openalex.org/C155647269","wikidata":"https://www.wikidata.org/wiki/Q243455","display_name":"Medicinal chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004148","descriptor_name":"Dioxolanes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006151","descriptor_name":"Guanosine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D006151","descriptor_name":"Guanosine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D011684","descriptor_name":"Purine Nucleosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011995","descriptor_name":"Recombination, Genetic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":true},{"descriptor_ui":"D017354","descriptor_name":"Point Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D024921","descriptor_name":"Drug Resistance, Multiple, Viral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1097/00042560-200201010-00002","doi":"https://doi.org/10.1097/00042560-200201010-00002","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00042560-200201010-00002","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},{"id":"doi:10.1097/00126334-200201010-00002","doi":"https://doi.org/10.1097/00126334-200201010-00002","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00126334-200201010-00002","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},{"id":"pmid:11782585","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11782585","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of acquired immune deficiency syndromes (1999)","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8299999833106995,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W1521635132","https://openalex.org/W1966952510","https://openalex.org/W1970203571","https://openalex.org/W1973685135","https://openalex.org/W1976683819","https://openalex.org/W1977521763","https://openalex.org/W1979161571","https://openalex.org/W1984605323","https://openalex.org/W1989692384","https://openalex.org/W1993061861","https://openalex.org/W2025994885","https://openalex.org/W2026323517","https://openalex.org/W2028143521","https://openalex.org/W2029986910","https://openalex.org/W2045197981","https://openalex.org/W2046134251","https://openalex.org/W2054829079","https://openalex.org/W2058530732","https://openalex.org/W2069366448","https://openalex.org/W2072246943","https://openalex.org/W2073063591","https://openalex.org/W2074495023","https://openalex.org/W2084702672","https://openalex.org/W2085459671","https://openalex.org/W2088997237","https://openalex.org/W2101033794","https://openalex.org/W2114339005","https://openalex.org/W2118732329","https://openalex.org/W2119997930","https://openalex.org/W2123314019","https://openalex.org/W2130516256","https://openalex.org/W2133759520","https://openalex.org/W2134713579","https://openalex.org/W2137698258","https://openalex.org/W2143773220","https://openalex.org/W2163138000","https://openalex.org/W2168188103","https://openalex.org/W2329745947","https://openalex.org/W2396863544","https://openalex.org/W2911949936","https://openalex.org/W3199273418"],"related_works":["https://openalex.org/W2071438157","https://openalex.org/W2133759520","https://openalex.org/W1972832783","https://openalex.org/W2015474565","https://openalex.org/W2101033794","https://openalex.org/W2123314019","https://openalex.org/W1995659161","https://openalex.org/W2106638078","https://openalex.org/W2088487539","https://openalex.org/W2071459281"],"abstract_inverted_index":{"Amdoxovir":[0],"([-]-beta-D-2,6-diaminopurine":[1],"dioxolane":[2],"[DAPD])":[3],"is":[4,16],"a":[5,27,46,184],"nucleoside":[6],"reverse":[7,100],"transcriptase":[8,101],"inhibitor":[9,102],"(NRTI)":[10],"with":[11],"activity":[12,44],"against":[13,45],"HIV-1.":[14],"DAPD":[15,51,79],"deaminated":[17],"in":[18,54,117,171,199],"vivo":[19],"by":[20,111,163,225],"adenosine":[21],"deaminase":[22],"to":[23,109,129,132,161,166,195,223,234],"(-)-beta-D-dioxolane":[24],"guanosine":[25],"(DXG),":[26],"highly":[28],"active":[29],"anti-HIV":[30],"compound.":[31],"The":[32,70,218],"median":[33],"50%":[34,71],"effective":[35],"concentrations":[36],"(EC":[37],"50":[38,75],")":[39,76],"+/-":[40,61,66],"SD":[41],"(representing":[42],"antiviral":[43],"laboratory-derived":[47],"HIV-1":[48,91],"isolate)":[49],"for":[50,94,216],"and":[52,64,80,87,136,138,141,151,156,177,227],"DXG":[53,81,112,167,196],"peripheral":[55],"blood":[56],"mononuclear":[57],"cells":[58],"were":[59,158],"4.0":[60],"2.2":[62],"micromol/L":[63],"0.25":[65],"0.17":[67],"micromol/L,":[68],"respectively.":[69],"cytotoxic":[72],"dose":[73],"(CC":[74],"of":[77,90,183],"both":[78],"was":[82,168],">500":[83],"micromol/L.":[84],"Recombinant":[85],"viruses":[86,125],"clinical":[88],"isolates":[89,173],"from":[92],"patients":[93],"whom":[95],"NRTI":[96],"therapy":[97],"and/or":[98],"nonnucleoside":[99],"(NNRTI)":[103],"combination":[104],"therapies":[105],"failed":[106],"remained":[107,221],"susceptible":[108,160,222],"inhibition":[110,162,224],"(less":[113],"than":[114],"fourfold":[115],"change":[116,198],"EC":[118,200],"50).":[119,201],"Similar":[120],"analysis":[121,182],"showed":[122],"that":[123],"recombinant":[124,172],"harboring":[126],"mutations":[127,215],"known":[128],"confer":[130],"resistance":[131,194,214,233],"NRTIs":[133],"(zidovudine,":[134],"lamivudine,":[135],"abacavir)":[137],"NNRTIs":[139],"(efavirenz":[140],"nevirapine)":[142],"as":[143,145],"well":[144],"the":[146,175,189,212,228],"multidrug":[147],"resistance-associated":[148],"mutation":[149,191],"Q151M":[150],"double":[152,179],"codon":[153],"insertions":[154],"(SS":[155],"SG)":[157],"also":[159,203],"DXG.":[164,217,235],"Resistance":[165],"observed":[169],"only":[170,188,208],"containing":[174,187,207],"65R":[176],"151M":[178,190],"mutations.":[180],"Phenotypic":[181],"site-directed":[185,205],"mutant":[186,220,230],"demonstrated":[192,231],"moderate":[193,232],"(<10-fold":[197],"We":[202],"examined":[204],"mutants":[206],"L74V":[209,219],"or":[210],"K65R,":[211],"characteristic":[213],"DXG,":[226],"K65R":[229]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}